Health Care/Hospital

BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration

China's influential innovative drug asset cooperation platform NEWARK, Del., June 9, 2025 /PRNewswire/ -- BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSee...

2025-06-09 14:51 4521

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the European Renal Association

* EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including IgA nephropathy (IgAN), minimal change disease (MCD), focal segmental glomerulosclerosis (FSG...

2025-06-09 14:16 2725

HIRONIC Successfully Hosts First Asia Innovation Summit 2025

SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th.

2025-06-07 18:21 3055

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 7, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated ...

2025-06-07 11:36 4005

EARLY CHRONIC KIDNEY DISEASE (CKD) INTERVENTION COULD SAVE AUSTRALIA $1 BILLION A YEAR[1]

SYDNEY, June 7, 2025 /PRNewswire/ -- New modelling highlights the potential societal, economic and environmental benefits of early chronic kidney disease (CKD) intervention which could change lives for thousands of Australians. Australia could save $25.2 billion in CKD-related costs and more than...

2025-06-06 23:00 3149

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World's First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery of novel and precise Cas nucleases and the development of safe and efficient cargo ...

2025-06-06 18:17 3900

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy

* Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All": — A subanalysis of the NefIgArd study demonstrates that early tr...

2025-06-06 16:12 2805

HIMSS Unites Global Healthcare Leaders to Shape the Future of Care: From Paris to Kuala Lumpur to Las Vegas

ROTTERDAM, Netherlands, June 6, 2025 /PRNewswire/ -- Thousands of health and technology leaders will gather to share critical health technology insights to optimize care delivery and improve health outcomes at the 2025 HIMSS European Health Conference & Exhibition from 10-12 June in Paris.

2025-06-06 14:02 2490

HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid

JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as  a globalleader in the development and  production of pharmaceut...

2025-06-06 14:00 2746

Kelun-Biotech Announces Approximately US$250 Million Placement

CHENGDU, China, June 6, 2025 /PRNewswire/ -- On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced the placement of 5,918,000 H shares under its general mandate, representing approximately 2.54% of the enlarged share capital of t...

2025-06-06 11:04 4598

Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market

KUALA LUMPUR, Malaysia, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta® Tongkat Ali,...

2025-06-06 10:00 3006

Pantai Hospital Kuala Lumpur Advances Adult Congenital Heart Care with First Minimally Invasive PDA Device Closure

KUALA LUMPUR, Malaysia, June 6, 2025 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone in cardiovascular care with the successful transcatheter device occlusion of a patent ductus arteriosus (PDA) in an adult patient with congenital heart disease — a first for the...

2025-06-06 09:00 2447

ZEISS CLARUS 700 Receives NMPA Approval in China

ZEISS Medical Technology expands retinal insights for ophthalmologists with ultra-widefield, high-resolution imaging capabilities JENA, Germany and SHANGHAI, June 6, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the CLARUS® 700 from ZEISS has received National Medical Produc...

2025-06-06 06:00 2512

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®

MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the  International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a h...

2025-06-05 20:00 2829

Waterdrop Inc. Announces First Quarter 2025 Unaudited Financial Results, Net profit rises 34.2% year-on-year

BEIJING, June 5, 2025 /PRNewswire/ -- On June 5, 2025, Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, unveiled its unaudited financial results for the three months ended March 31, 2025. During the quarter, W...

2025-06-05 19:58 5124

Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal

SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughpu...

2025-06-05 19:40 3218

Astellas Chooses Veeva Vault CRM as Global Standard

Vault CRM will support Astellas' commercial agility and execution SINGAPORE, June 5, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Astellas has chosenVeeva Vault CRM  globally and Veeva China CRM

2025-06-05 10:00 3464

JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao

SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Car...

2025-06-05 09:04 3858

Proto Axiom and St Vincent's Curran Foundation join forces to host Australia's largest medical pitch day

SYDNEY, June 5, 2025 /PRNewswire/ -- Proto Axiom, Australia's leading biotech incubator, and St Vincent's Curran Foundation unite to launch Challenger Pitch for Health, the nation's largest medical and biotech pitch event, in Sydney in March 2026. Challenger Pitch for Health will award $500,000 ...

2025-06-05 07:55 2350

ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy

VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA Congress demonstr...

2025-06-05 06:01 2587
1 ... 102103104105106107108 ... 541